NEW YORK, May 15, 2026
MiNK Therapeutics, Inc. reported first quarter 2026 financial results while highlighting major clinical and translational advances for its allogeneic invariant natural killer T (allo-iNKT) cell therapy platform. The company announced the initiation of a randomized Phase 2 clinical trial evaluating agenT-797 in patients with severe acute lung injury and acute respiratory distress syndrome (ARDS), marking an important step toward prospective validation of its off-the-shelf cell therapy approach. Preliminary data from the study are expected in the second half of 2026.
MiNK stated that agenT-797 is designed as an off-the-shelf iNKT cell therapy that can be administered without lymphodepletion or HLA matching, offering potential advantages in rapidly progressing critical illnesses where speed, scalability, and tolerability are essential. The ongoing study is evaluating agenT-797 plus standard of care versus placebo in critically ill adults suffering from severe pneumonia-related respiratory failure meeting global ARDS criteria.
Phase 2 Trial Targets Severe Lung Injury and Critical Care
According to MiNK Therapeutics, Inc., the randomized trial has received authorization from the Ukraine Ministry of Health and operates under an active U.S. Investigational New Drug (IND) application, with planned U.S. site activation pending FDA clearance. The company designed the study with a seamless Phase 2/3 framework to potentially accelerate later-stage development if clinical outcomes are confirmed.
ARDS remains one of the most serious unmet needs in critical care medicine, affecting approximately 3 million patients globally and nearly 200,000 patients annually in the United States. Mortality rates remain extremely high, ranging from 40% to 50%, and there are currently no approved pharmacologic therapies proven to reduce mortality. MiNK believes agenT-797 may help restore immune balance, improve respiratory recovery, reduce secondary infections, and enhance survival outcomes in critically ill patients.
The company also presented new translational and clinical findings at the AACR Annual Meeting and the ASGCT 2026 Annual Meeting, further supporting the biologic rationale for its iNKT platform. In heavily pretreated PD-1 refractory gastroesophageal cancer, investigator-sponsored Phase 2 data showed a 77% disease control rate and long-term survival exceeding 20 months in some patients receiving immune induction prior to chemotherapy.
Advertisement
Translational Data Highlight Context-Dependent Immune Activity
At ASGCT, MiNK reported that the same agenT-797 product demonstrated distinct immune responses depending on disease context. In solid tumor patients, the therapy generated a TH1 pro-inflammatory signature consistent with anti-tumor immune activation, while in ARDS patients it produced a TH2 anti-inflammatory signature associated with immune restoration and lung recovery. The findings reinforce MiNK’s broader strategy of applying iNKT therapy across diseases driven by immune dysfunction.
Beyond its lead clinical programs, MiNK continues expanding its platform through non-dilutive collaborations and externally funded development initiatives. During the quarter, the company partnered with pediatric oncology consortium C-Further to develop a PRAME-targeted TCR-engineered iNKT therapy for pediatric cancers, supported by approximately $1.1 million in non-dilutive funding and potential downstream commercial participation.
Financially, MiNK ended the first quarter of 2026 with approximately $9.5 million in cash and cash equivalents while continuing efforts to reduce operating burn and maintain capital-efficient development. The company also completed repayment of approximately $5.2 million related to the Agenus convertible note, simplifying its balance sheet while maintaining focus on advancing high-priority clinical programs.
Source: MiNK Therapeutics press release
